Hope for families as Government delivers

SYDNEY, 11 May 2021: After more than a decade of lobbying the Government to provide funding for preimplantation genetic diagnosis (PGD) the Morrison Government has announced $95.9 million will be allocated to new tests on the MBS for genetic testing of embryos for specific chromosomal abnormalities.

Funding will financially support parents who carry a genetic disorder to screen their embryos during an IVF
cycle, ensuring they don’t pass on a disease or potentially life threatening condition to their children.
 
"We congratulate the Government for responding to our submission and providing this much needed
funding," CEO of Genea, Tomas Stojanov said.
 
Genea submitted the application after watching the heartache suffered by patients desperate for a baby.
"These families often already had a sick child or had a child die," Genea Medical Director Associate Professor
Mark Bowman said. "But PGD is an expensive process and people who need it haven’t been able to access it
due to financial constraints."
 
At present PGD, does not attract any Medicare rebate and can add as much as $6200 to the cost of a regular
IVF cycle. The procedure, which involves analysing embryos before implanting them into the would-be
mother, is the only way couples carrying a genetic condition such as Cystic fibrosis, Fragile X or Huntington's
disease can have a healthy baby.
 
Genea is able to detect more than 350 genetic diseases. "We pioneered PGD, our expertise and techniques
are amongst the best in the world. Many clinics have followed our lead and modelled their approach to
embryo biopsy on ours," Dr Bowman said.
 
The announcement has been welcomed by couples such as Haely and Alastair O’Neill, Haely is a carrier of
Retinitis Pigmentosa (RP) and didn’t want to pass the genetic condition onto her offspring. Whilst she isn’t
affected, Haely’s father was diagnosed in his twenties and is legally blind, Haely had witnessed her father live
a challenging life.
 
“Dad always said he didn’t want our children to live with the disability that had made his world so hard. In
our family, eight males have been affected by Retinitis Pigmentosa over the past 50 years but I am the final
female carrier. By having IVF and accessing PGD we were able to rid the disease entirely from our family.”
 
The Drummoyne couple had to make numerous sacrifices to afford PGD, “we delayed buying a home, we
didn’t go on a honeymoon, we gave up a lot.”
 
The couple had three stimulated cycles and a total of 12 embryos tested, of those many were either affected
or a carrier, only two were appropriate for transfer. On the 22nd of June 2018, Heidi O’Neill was born to
two very grateful parents. Two years later on 13 July 2020, Heidi then became a big sister and baby Astrid
joined the family, after another frozen embryo transfer at Genea.
 
“We are so thankful the science is available, and we accessed the leading PGD clinic in Australia.”
 
Haely praised the Government on behalf of future patients requiring PGD, "if parents want to have PGD to
prevent having a child with a debilitating disease, it makes sense for the government to financially support
their choice," said Haely.
 
"It is a momentous week, one that should be celebrated, we look forward to hearing more details around
Minister Hunt’s announcement." Dr Stojanov said.
 
Other counties including the United Kingdom, New Zealand, France and the Netherlands all provide some
public subsidy for the medical procedure.
Download a PDF of the press release

Media Contact

Alice Ross
M: 0421 741 737
E: alice.ross@genea.com.au

Background
Genea is one of Australia’s leading providers for infertility, IVF and other assisted conception treatment with 35 years of experience in the field. The company has long been a fertility pioneer, with research and technologies developed in-house virtually doubling IVF success rates in the mid-nineties and continuing to improve outcomes today.

In Australia, Genea lead the way in investigating and developing PGD and our expertise and techniques are amongst the best in the world. Genea launched chromosome testing of embryos in 1995 and expanded that treatment to offering single gene testing in 1998. Genea’s PGD testing now detects more than 350 genetic diseases.